| Gastrointestinal Disorder Therapeutics to 2016 - High | | | | increased the competition, driving the consolidation |
| Unmet Needs Triggering Strong Growth in Crohn's | | | | further. The increasing pressure has also driven |
| Disease and Irritable Bowel Syndrome Markets | | | | companies to enter into licensing agreements. This |
| | | | allows companies to expand product portfolio and |
| Summary | | | | improve their competitive positions in the market. |
| Gastrointestinal Disorders Therapeutics to 2016 - High | | | | |
| Unmet Needs Triggering Strong Growth in Crohn's | | | | Scope |
| Disease and Irritable Bowel Syndrome Marketsâ€, | | | | The scope of this report includes: |
| provides in-depth analysis of the unmet needs, drivers | | | | Annualized market data for the gastrointestinal |
| and barriers that affect the global gastrointestinal | | | | disorder therapeutics market from 2001 to 2009, |
| disorder therapeutics market. It analyzes the markets | | | | forecast forward to 2016 |
| for gastrointestinal disorder therapeutics in the US, the | | | | Analysis of the leading therapeutic segments. These |
| top five countries in Europe (the UK, Germany, France, | | | | include crohn disease, ulcerative colitis, irritable bowel |
| Italy and Spain) and Japan. Treatment usage patterns, | | | | syndrome, and gastroesophageal reflux disease. |
| sales, price and volume are forecast until 2016 for the | | | | Analysis of the gastrointestinal disorder therapeutics |
| key geographies as well as the leading therapeutic | | | | market in the leading geographies of the world, which |
| segments. Further, the report provides competitive | | | | include the US, the UK, Germany, France, Italy, Spain, |
| benchmarking for the leading companies and analyzes | | | | and Japan |
| the mergers, acquisitions and licensing agreements that | | | | Market characterization of the gastrointestinal disorder |
| shape the global markets. | | | | therapeutics market including market size, annual cost |
| It is built using data and information sourced from | | | | of therapy, and treatment usage patterns |
| proprietary databases, primary and secondary | | | | Key drivers and barriers that have a significant impact |
| research and in-house analysis by GBI Research team | | | | on the market |
| of industry experts. | | | | Coverage of pipeline molecules in various phases of |
| Finds that the gastrointestinal disorder therapeutics | | | | drug development |
| market will decline during the period 2009-2016. This | | | | Competitive benchmarking of leading companies. The |
| decline is primarily driven by the negative growth of | | | | key companies studied in this report are AstraZeneca, |
| gastroesophageal reflux disease (GERD) therapeutics | | | | Takeda pharmaceutical company Ltd., Eisai |
| market which is attributed to loss of drug patents and | | | | pharmaceuticals Nycomed, Pfizer Inc, GlaxoSmithKline, |
| entry of generics. However, other key gastrointestinal | | | | Novartis AG, and Johnson & Johnson. |
| disorders such as crohn disease and irritable bowels | | | | Key M&A activities, licensing agreements, that |
| syndrome therapeutics market will continue to grow | | | | have taken place between 2008 and 2009 in the |
| due to strong late stage pipeline that will address the | | | | global gastrointestinal disorder therapeutics market |
| unmet needs. The global gastrointestinal disorder | | | | |
| therapeutics market is a highly fragmented market and | | | | Reasons to buy |
| big players are facing stiff competition. The | | | | The report will enhance your decision making capability. |
| forthcoming patent expiries of major drugs have | | | | |